Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 178Bortezomib 100Lenalidomide 90daratumumab 47Melphalan 46Thalidomide 44pomalidomide 43Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14isatuximab 12ixazomib 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × In Situ Hybridization, Fluorescence × Plasma cell × Clear all
NCT00217438 2015-08-21

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 3 Completed
130 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡